Previous close | 1.1200 |
Open | 1.1400 |
Bid | 1.0400 x 5600 |
Ask | 1.0700 x 5600 |
Day's range | 1.0200 - 1.1600 |
52-week range | 0.8500 - 5.5300 |
Volume | |
Avg. volume | 8,308,417 |
Market cap | 216.835M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6300 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.16 |
Detailed Analysis of Financial Performance and Future Outlook
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
SOMERVILLE, Mass., May 09, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.